Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On January 4, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to eight newly-hired employees, totaling 49,000 shares.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

On January 4, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to eight newly-hired employees, totaling 49,000 shares. The options have an exercise price of $2.26 per share, in line with the stock's closing price on the grant date, December 31, 2021. The vesting period spans four years, with 25% vesting after the first anniversary and the remainder quarterly, contingent upon continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing new talent in the biopharmaceutical sector focused on kidney disease.

Positive

Inducement grants of 49,000 shares to new employees may enhance talent retention and motivation.
Options granted at a market price can foster alignment with shareholder interests.

Negative

None.

Argus Session date unavailable

-5.08% session move Open Argus

Details

News Market Reaction – AKBA

The recorded move for AKBA in the trading session of this news was -5.08%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/04/2022 - 04:05 PM EST

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 31, 2021, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.26 per share, which is equal to the closing price of Akebia's common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee's continued service with the Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia's Inducement Award Program and a stock option agreement covering the grant.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301453901.html

SOURCE Akebia Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was announced by Akebia Therapeutics on January 4, 2022?

Akebia Therapeutics announced the grant of 49,000 stock options to eight new employees as inducements for their employment.

What is the exercise price of the stock options granted by Akebia?

The exercise price of the stock options is $2.26 per share, equal to the closing price on the grant date.

How long is the vesting period for the stock options granted by Akebia?

The stock options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly.

What rule did Akebia follow for the recent stock option grants?

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

How many shares were granted to each new employee at Akebia?

The total of 49,000 shares were granted among eight newly-hired employees.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)